Glecaprevir-pibrentasvir for chronic hepatitis C – a clinical review
- Gastroenterology & Hepatology: Open Access
Alireza FakhriRavari,1 Minh Hien Chau Nguyen,2 Roberto Clemente Garcia3
PDF Full Text
Hepatitis C virus (HCV) infection has a significant global burden with complications that include hepatocellular carcinoma, decompensated cirrhosis, and the need for liver transplantation to avoid death. Although many treatment options are available for treatment of HCV infections, treatment often requires at least 12 weeks of therapy, which may be complicated by HCV genotype, the need for addition of ribavirin, presence of advanced liver disease, end-stage kidney disease, prior treatment failure, and presence of resistance-associated substitutions. Glecaprevir-pibrentasvir is a pangenotypic, ribavirin-free treatment option approved for ages 3 years or older. This regimen can be used in patients with end-stage kidney disease, has a high-barrier to resistance, and has a shorter treatment duration of 8 weeks for most patients. The purpose of this review is to evaluate the safety and efficacy of this regimen in adults and children who are infected with HCV, which may be the only treatment option for certain patients.
HCV, hepatitis C, glecaprevir, ABT-493, pibrentasvir, ABT-530, Mavyret, AASLD, American association for the study of liver diseases, BCRP, breast cancer resistance protein, CI, confidence interval, CYP, cytochrome P450, DAA, direct-acting antiviral agent, GLE, glecaprevir, HBV, hepatitis B virus, HCV, hepatitis c virus, HIV, human immunodeficiency virus, IDSA, infectious diseases society of America, OATP, organic anion-transporting Protein, PIB, pibrentasvir, RAS, resistance-associated substitution, RNA, ribonucleic acid, SOF, sofosbuvir, SVR, sustained virologic response, VEL, velpatasvir, VOX, voxilaprevir